All News
Predicting Treatment Response in Inflammatory Muscle Disorders
d
MedPage Today
Rheumatologists looking for clues to whether their patients with certain inflammatory myopathies will improve on immunosuppressive drugs may find them in a new study appearing in Arthritis Care & Research.
Read Article
BMI Most Impairs Treatment Response in Rheumatoid Arthritis
Using a large cohort of rheumatoid arthritis (RA) patients, Tumor-Necrosis Factor inhibitors (TNFi) were compared to non-TNFi biologic therapies and showed that poorer responses were seen in obese and underweight patients, with no clear superiority of non-TNFi therapy over TNFi therapy in an
Read Article
Subsets of scleroderma defined by autoantibodies. #RWCS2022 @RWCSmtg https://t.co/ywe0yrHmWd
Dr. John Cush RheumNow ( View Tweet)
Many failed clinical trials in Scleroderma in the past. #RWCS2022 @RWCSmtg https://t.co/2PBfHAnqWu
Dr. John Cush RheumNow ( View Tweet)
Predicting Treatment Response in Inflammatory Muscle Disorders
Rheums looking for clues to whether their patients w/certain inflammatory myopathies will improve on immunosuppressive drugs may find them in a new study in Arthritis Care & Research.
https://t.co/kXFIEMTbkb https://t.co/UbO7nSsdAY
Links:
Dr. John Cush RheumNow ( View Tweet)
Significant mortality risk with scleroderma renal crisis. #RWCS2022 @RWCSmtg https://t.co/vIm0xDEjB3
Dr. John Cush RheumNow ( View Tweet)
Scleroderma ANA associations thru the ages. Dr. Virginia Steen
@RWCSmtg #RWCS2022 https://t.co/U64gpnCgS8
Dr. John Cush RheumNow ( View Tweet)
Would combination biologics work? Maybe according to this collection of antecdotal use. #RWCS2022 @RWCSmtg https://t.co/VJdINyqLQt
Dr. John Cush RheumNow ( View Tweet)
NOR-DRUM study shows that TDM, therapeutic drug monitoring, is beneficial. Study of RA, PSA, AS, Crohn's, UC Rheums don't do this, should they? #RWCS2022 @RWCSmtg https://t.co/Dc6mgr5jrL
Dr. John Cush RheumNow ( View Tweet)
IMPACT2 shows what we see in most PSA trials- little x-ray progression. #RWCS2022 @RWCSmtg https://t.co/uYXHB0s8g0
Dr. John Cush RheumNow ( View Tweet)
Dr Artie Kavanaugh presents comparison of targeted therapies in different inflammatory disorders. #RWCS2022 @RWCSmtg https://t.co/cX00RUOgAq
Dr. John Cush RheumNow ( View Tweet)
Fecal transplant (FMT) failed to help #PsA, small trial, unexpected result. #RWCS2022 @RWCSmtg https://t.co/zKq6FONuwk
Dr. John Cush RheumNow ( View Tweet)
Proposed new pathways involving the inhibition or deletion of kindlin-2, Stat3 and Runx2 in articular chondrocytes that promotes cartilage degradation and osteoarthritis -- potential new therapeutic target for OA https://t.co/EFgGctoYJY
Dr. John Cush RheumNow ( View Tweet)
Retrospective study of 98 patients with X-linked agammaglobulinemia (XLA) shows arthritis seen in 46% - more oligo- than polyarthritis, affecting . Knee, hip, and ankle. IVIG response rates around 70%; many w/ arthritis had missense mutation https://t.co/lreW5hkyr9
Links:
Dr. John Cush RheumNow ( View Tweet)
Voriconazole-induced synovitis, enthesitis and periostitis described in woman treated for invasive aspergillosis. She had polyarthralgias, synovitis (MRI and US), and periostitis on xray. Voriconazole prev. caused periostitis; now drug induced arthritis? https://t.co/10MnYvD3sA
Links:
Dr. John Cush RheumNow ( View Tweet)
New 2021 JIA guidelines w 55 recommendations, 36 conditional and 19 strong. #RWCS2022 @RWCSmtg Dr Susan Shenoi https://t.co/CMETQeOdch
Dr. John Cush RheumNow ( View Tweet)
ACR RISE registry study looked at Rx of 3276 Sarcoidosis pts from 184 rheum practices finds 59.3% rx w/ steroids (24% prolonged steroids). and 12.1 Rx w/ biologics or tsDMARDs, mostly TNFi (inflx). But wide practice-level variations in Rx https://t.co/95CEDai2uN
Links:
Dr. John Cush RheumNow ( View Tweet)
MMWR study of shows 2 dose mRNA COVID vax during pregnancy was 61% effective preventing infant COVID. Among 176 infants hosp w/ COVID-19, 84% were born to mothers who were not vaccinated during pregnancy.https://t.co/mWgHHcL05u
Links:
Dr. John Cush RheumNow ( View Tweet)
Saphnelo (anifrolumab) has been approved in the European Union as an add-on therapy for the treatment of adult with moderate to severe, active, autoantibody-positive systemic lupus erythematosus (SLE), despite receiving standard therapy.https://t.co/fdZAFFDrYW
Links:
Dr. John Cush RheumNow ( View Tweet)
Study of 25/306 SLE patients (8.2%) who developed 29 episodes of Pulmonary Hemorrhage (PH). 1st manifestation . PH assoc w/ Renal dz, high SLE activity during PH; PH mortality w/ Renal failure & mech ventilation. https://t.co/ydJkgf5BFB
Links:
Dr. John Cush RheumNow ( View Tweet)